Log in

NASDAQ:SYNH - Syneos Health Stock Price, Forecast & News

$56.05
-1.31 (-2.28 %)
(As of 12/15/2019 04:06 AM ET)
Today's Range
$55.99
Now: $56.05
$57.49
50-Day Range
$47.93
MA: $52.68
$57.41
52-Week Range
$36.26
Now: $56.05
$57.96
Volume321,343 shs
Average Volume337,692 shs
Market Capitalization$5.82 billion
P/E Ratio21.39
Dividend YieldN/A
Beta1.5
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYNH
CUSIPN/A
Phone919-876-9300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.39 billion
Cash Flow$5.31 per share
Book Value$27.67 per share

Profitability

Net Income$24.28 million

Miscellaneous

Employees24,000
Market Cap$5.82 billion
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive SYNH News and Ratings via Email

Sign-up to receive the latest news and ratings for SYNH and its competitors with MarketBeat's FREE daily newsletter.


Syneos Health (NASDAQ:SYNH) Frequently Asked Questions

What is Syneos Health's stock symbol?

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

How were Syneos Health's earnings last quarter?

Syneos Health Inc (NASDAQ:SYNH) posted its earnings results on Thursday, October, 31st. The company reported $0.87 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.82 by $0.05. The firm earned $1.18 billion during the quarter, compared to analyst estimates of $1.18 billion. Syneos Health had a net margin of 1.86% and a return on equity of 10.13%. The business's revenue was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.75 EPS. View Syneos Health's Earnings History.

When is Syneos Health's next earnings date?

Syneos Health is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Syneos Health.

What guidance has Syneos Health issued on next quarter's earnings?

Syneos Health updated its FY19 earnings guidance on Thursday, October, 31st. The company provided EPS guidance of $3.17-3.27 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.16. The company issued revenue guidance of $4.63-4.69 billion, compared to the consensus revenue estimate of $4.69 billion.

What price target have analysts set for SYNH?

9 brokerages have issued 12-month price targets for Syneos Health's shares. Their forecasts range from $48.00 to $68.00. On average, they expect Syneos Health's share price to reach $60.14 in the next twelve months. This suggests a possible upside of 7.3% from the stock's current price. View Analyst Price Targets for Syneos Health.

What is the consensus analysts' recommendation for Syneos Health?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syneos Health.

Has Syneos Health been receiving favorable news coverage?

News stories about SYNH stock have been trending negative this week, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Syneos Health earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Syneos Health.

Who are some of Syneos Health's key competitors?

What other stocks do shareholders of Syneos Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Icon (ICLR), Netflix (NFLX), Skyworks Solutions (SWKS), Square (SQ), Constellation Brands (STZ), AT&T (T), UnitedHealth Group (UNH), Visa (V) and Jazz Pharmaceuticals (JAZZ).

Who are Syneos Health's key executives?

Syneos Health's management team includes the folowing people:
  • Mr. Alistair Macdonald, CEO & Director (Age 49)
  • Mr. Jason M. Meggs, Chief Financial Officer (Age 43)
  • Mr. Jonathan Olefson, Gen. Counsel & Corp. Sec. (Age 43)
  • Mr. Michael Adam Bell, Consultant (Age 63)
  • Mr. Robert Parks, Exec. VP & Chief Accounting Officer

Who are Syneos Health's major shareholders?

Syneos Health's stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (1.94%), Boston Partners (1.32%), GW&K Investment Management LLC (1.09%), Voya Investment Management LLC (0.74%), Pictet Asset Management Ltd. (0.66%) and Peregrine Capital Management LLC (0.64%). Company insiders that own Syneos Health stock include Alistair Macdonald, Christopher L Gaenzle, H Lee Equity Fund Vi Thomas, Jason M Meggs and Jonathan Olefson. View Institutional Ownership Trends for Syneos Health.

Which institutional investors are selling Syneos Health stock?

SYNH stock was sold by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, State Street Corp, Man Group plc, AMI Asset Management Corp, Boston Partners, SG Americas Securities LLC, Dupont Capital Management Corp and Kornitzer Capital Management Inc. KS. View Insider Buying and Selling for Syneos Health.

Which institutional investors are buying Syneos Health stock?

SYNH stock was purchased by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Boston Advisors LLC, Pictet Asset Management Ltd., State of New Jersey Common Pension Fund D, Peregrine Capital Management LLC, Massachusetts Financial Services Co. MA, Congress Asset Management Co. MA and Campbell Newman Asset Management Inc.. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs and Jonathan Olefson. View Insider Buying and Selling for Syneos Health.

How do I buy shares of Syneos Health?

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Syneos Health's stock price today?

One share of SYNH stock can currently be purchased for approximately $56.05.

How big of a company is Syneos Health?

Syneos Health has a market capitalization of $5.82 billion and generates $4.39 billion in revenue each year. The company earns $24.28 million in net income (profit) each year or $2.62 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe.View Additional Information About Syneos Health.

What is Syneos Health's official website?

The official website for Syneos Health is http://www.syneoshealth.com/.

How can I contact Syneos Health?

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]


MarketBeat Community Rating for Syneos Health (NASDAQ SYNH)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  482 (Vote Outperform)
Underperform Votes:  390 (Vote Underperform)
Total Votes:  872
MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote "Outperform" if you believe SYNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel